OMNIlife science™, Inc. Surpasses 17,000 Procedures Milestone for OMNIBotics® Robotic-Assisted Total Knee Replacements

RAYNHAM, Mass., Oct. 5, 2017 /PRNewswire/ -- OMNIlife science, Inc. ("OMNI™"), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced today that surgeons have completed more than 17,000 total knee replacements worldwide using the OMNIBotics robotic-assisted total knee replacement technology platform. The OMNIBotics system enables optimized implant placement using robotics driven by OMNI's proprietary ART™ software. Surgeons can efficiently plan a procedure that is specific to each patient using a patented intra-operative 3-D modeling technique that eliminates the need for preoperative CT scans or x-rays. This results in a more precise alignment of the knee implant that many surgeons believe can lead to more rapid recovery and a more natural feeling knee replacement.

In addition to the clinical benefits, the OMNIBotics system provides proven savings per episode of care through a reduced learning curve for the surgeon and O.R. staff as well as a fast case-to-case turnaround and a compact physical footprint which improves efficiency. There is no capital investment cost for the hospital and no annual maintenance or software upgrade fees. This makes the OMNIBotics system a more cost-effective way for healthcare providers to offer robotic-assisted total knee replacement surgery to their patients.

"As one of the first surgeons to adopt OMNIBotics and having performed more than 1500 procedures, this significant milestone validates my experience with the technology," said Ronald LaButti, DO, FAOAO, orthopedic surgeon with Advanced Orthopedics of Oklahoma and Oklahoma Surgical Hospital in Tulsa, OK. "I am committed to providing orthopedic care that is second to none and find that the precision of the OMNIBotics patient-specific procedure enables my patients to recover more quickly and results in excellent clinical outcomes as well as very satisfied patients."

Market research estimates that in the next 5 years, more than 20% of total knee replacement procedures will be performed using robotic-assistance. OMNI has anticipated this demand and is focused on designing breakthrough complementary technologies like their recently FDA cleared Active Spacer which, for the first time, provides the surgeon with a quantitative tool to actively manage the tension on ligaments and pressures in the knee joint itself  with dynamic real-time feedback.

"OMNI has been at the forefront of robotic-assisted total knee replacement technology since the initial introduction of our first robotic total knee systems in 2010 and passing this 17,000 robotic- assisted TKA procedure milestone shows that we are still going strong," stated Carl Knobloch, OMNI's Vice President of Marketing.  "We continue to see increased interest in our latest OMNIBotics technology from surgeons, patients and hospitals.  With the pending addition to the OMNIBotics platform of our recently FDA cleared Active Spacer robotic soft tissue balancing technology, we expect the rate of adoption and case volumes to increase significantly in the coming year.

ABOUT OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon's ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

FORWARD LOOKING STATEMENTS

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms "plans," "believes" or similar expressions are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management's current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI's markets, decrease in the demand for OMNI's products, delays in OMNI's product research and development cycles, decreases in the use of OMNI's principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI's current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI's current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI's sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI's products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.

CONTACT
Cindy Holloway, Director of Marketing Communications Phone: (508) 824-2444
[email protected]

SOURCE OMNIlife science, Inc.

Related Links

http://www.omnils.com